RNA-targeting
small-molecule therapeutics is an emerging field
hindered by an incomplete understanding of the basic principles governing
RNA–ligand interactions. One way to advance our knowledge in
this area is to study model systems where these interactions are better
understood, such as riboswitches. Riboswitches bind a wide array of
small molecules with high affinity and selectivity, providing a wealth
of information on how RNA recognizes ligands through diverse structures.
The cobalamin-sensing riboswitch is a particularly useful model system,
as similar sequences show highly specialized binding preferences for
different biological forms of cobalamin. This riboswitch is also widely
dispersed across bacteria and therefore holds strong potential as
an antibiotic target. Many synthetic cobalamin forms have been developed
for various purposes including therapeutics, but their interaction
with cobalamin riboswitches is yet to be explored. In this study,
we characterize the interactions of 11 cobalamin derivatives with
three representative cobalamin riboswitches using in vitro binding
experiments (both chemical footprinting and a fluorescence-based assay)
and a cell-based reporter assay. The derivatives show productive interactions
with two of the three riboswitches, demonstrating simultaneous plasticity
and selectivity within these RNAs. The observed plasticity is partially
achieved through a novel structural rearrangement within the ligand
binding pocket, providing insight into how similar RNA structures
can be targeted. As the derivatives also show in vivo functionality,
they serve as several potential lead compounds for further drug development.